

Published in final edited form as:

*Biochem J.* 2011 July 1; 437(1): . doi:10.1042/BJ20101804.

## Stereospecific reduction of 5 $\beta$ -reduced steroids by human ketosteroid reductases of the AKR (aldo-keto reductase) superfamily: role of AKR1C1–AKR1C4 in the metabolism of testosterone and progesterone via the 5 $\beta$ -reductase pathway

Yi Jin, A. Clementina Mesaros, Ian A. Blair, and Trevor M. Penning<sup>1</sup>

<sup>1</sup>Department of Pharmacology and Centers of Excellence in Environmental Toxicology and Cancer Pharmacology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6084, U.S.A

### Abstract

Active sex hormones such as testosterone and progesterone are metabolized to tetrahydrosteroids in the liver to terminate hormone action. One main metabolic pathway, the 5 $\beta$ -pathway, involves 5 $\beta$ -steroid reductase (AKR1D1, where AKR refers to the aldo-keto reductase superfamily), which catalyses the reduction of the 4-ene structure, and ketosteroid reductases (AKR1C1–AKR1C4), which catalyse the subsequent reduction of the 3-oxo group. The activities of the four human AKR1C enzymes on 5 $\beta$ -dihydrotestosterone, 5 $\beta$ -pregnane-3,20-dione and 20 $\beta$ -hydroxy-5 $\beta$ -pregnan-3-one, the intermediate 5 $\beta$ -dihydrosteroids on the 5 $\beta$ -pathway of testosterone and progesterone metabolism, were investigated. Product characterization by liquid chromatography–MS revealed that the reduction of the 3-oxo group of the three steroids predominantly favoured the formation of the corresponding 3 $\beta$ -hydroxy steroids. The stereochemistry was explained by molecular docking. Kinetic properties of the enzymes identified AKR1C4 as the major enzyme responsible for the hepatic formation of 5 $\beta$ -tetrahydrosteroid of testosterone, but indicated differential routes and roles of human AKR1C for the hepatic formation of 5 $\beta$ -tetrahydrosteroids of progesterone. Comparison of the kinetics of the AKR1C1–AKR1C4-catalysed reactions with those of AKR1D1 suggested that the three intermediate 5 $\beta$ -dihydrosteroids derived from testosterone and progesterone are unlikely to accumulate in liver, and that the identities and levels of 5 $\beta$ -reduced metabolites formed in peripheral tissues will be governed by the local expression of AKR1D1 and AKR1C1–AKR1C3.

### Keywords

dihydrosteroid; hydroxysteroid dehydrogenases; liquid-chromatography–MS (LC–MS); steroid metabolism; tetrahydrosteroid

### INTRODUCTION

The levels of active steroid hormones are tightly regulated through a balance of synthesis and metabolism. Liver is the primary site of metabolism for steroid hormones containing a

© The Authors

<sup>1</sup>To whom correspondence should be addressed: penning@upenn.edu.

#### AUTHOR CONTRIBUTION

Yi Jin and Trevor Penning developed the overall experimental strategy and wrote the paper. Yi Jin performed the majority of the experiments. Clementina Mesaros and Ian Blair performed LC–MS analysis.

4-3-one functionality, which include active hormones such as testosterone and progesterone. These active hormones are converted into THS (tetrahydrosteroids), which are conjugated in phase 2 reactions leading to elimination [1,2]. The metabolic sequence for the formation of THS involves the pathways shown in Scheme 1. In the first step, the 4-ene moiety of the steroid is reduced by 5 $\alpha$ - or 5 $\beta$ -steroid reductases to form the respective DHS (dihydrosteroids). In the subsequent step, the 3-oxo group of DHS is reduced by ketosteroid reductases to form THS. 5 $\alpha$ -Steroid reductases and the 5 $\beta$ -pathway have been a focus since the potent androgen 5 $\alpha$ -DHT (5 $\alpha$ -dihydrotestosterone, also called 17 $\beta$ -hydroxy-5 $\alpha$ -androstane-3-one) is formed from testosterone [3,4]. In contrast, less is known about the 5 $\beta$ -pathway since 5 $\beta$ -steroid reductase, which is a member of the AKR (aldo-keto reductase) family (see <http://www.med.upenn.edu/akr>), named as AKR1D1, is historically believed to be only involved in steroid inactivation [5,6]. It is now recognized that the 5 $\beta$ -reduced steroids are not inactive. 5 $\beta$ -Pregnane-3,20-dione is a potent ligand for the PXR (pregnane X receptor) and the constitutive androstane receptor [7]. Activation of the hepatic PXR leads to induction of CYP3A4 (cytochrome P450 3A4), which is responsible for the metabolism of approximately 50 % of drugs consumed. Additionally, 5 $\beta$ -reduced pregnanes are important neuroactive steroids [8] and have been implicated in vasorelaxation [9] and human parturition [10,11].

Enzymes most implicated in the metabolism of 5 $\alpha$ -DHS to the corresponding isomeric 3 $\alpha$ -, 5 $\alpha$ -THS are the NADPH-dependent HSDs (hydroxysteroid dehydrogenases) of the AKR1C subfamily [12,13]. The four human isoforms are: AKR1C1 (also known as 20 $\beta$ -HSD), AKR1C2 (also known as human type 3 $\beta$ -HSD), AKR1C3 (also known as human type 2 $\beta$ -HSD and type 5 $\beta$ -HSD) and AKR1C4 (also known as human type 1 $\beta$ -HSD). These enzymes are highly homologous in sequence (identity >86 %), but have different tissue expression properties. All isoforms are abundantly expressed in liver at comparable levels, but AKR1C4 is found only in liver, whereas AKR1C1–3 are differentially expressed in the lung, prostate, mammary gland and testis [13]. Individual human AKR1C enzymes catalyse ketosteroid reduction at the 3-, 17-, or 20-position to varying degrees depending on the substrate. Individual isoforms can reduce the same steroid with different stereochemical outcomes and the stereochemistry of the reaction is often steroid-dependent [4,14,15]. Although the four human AKR1C enzymes are implicated in reducing both 5 $\alpha$ - and 5 $\beta$ -DHS, only their involvement in the reduction of 5 $\alpha$ -DHT has been thoroughly investigated [4]. Incomplete kinetic data have been reported for the reduction of 5 $\beta$ -reduced steroids by human AKR1C enzymes [16–20], but there has not been any rigorous metabolite identification (i.e. by MS). Nor has there been any attempt to distinguish the role of individual human AKR1C isoforms on reducing 5 $\beta$ -DHS in testosterone and progesterone metabolism.

It is known that the major metabolites of testosterone include androstanediol (or 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol, a 3 $\alpha$ ,5 $\alpha$ -THS) and etiocholanolone (5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol, a 3 $\alpha$ ,5 $\beta$ -THS) [1]. Differential stereochemical and kinetic behaviour of human AKR1C enzymes established their different roles in the formation of 5 $\alpha$ -THS during testosterone metabolism [4]. Specifically, with 5 $\alpha$ -DHT, the intermediate steroid on the 5 $\alpha$ -pathway, AKR1C1 acts as a reductive 3 $\beta$ -HSD to yield 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol as the main product, AKR1C2 and AKR1C4 catalyse the efficient formation of 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol, and AKR1C3 catalyses the slow formation of a mixture of 3 $\alpha$ ,5 $\alpha$ - and 3 $\alpha$ ,5 $\beta$ -products. The liver-specific expression of AKR1C4 limits this enzyme to the clearance of 5 $\alpha$ -DHT in that organ. However, AKR1C1 and AKR1C2 are believed to be responsible for the formation of 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol [a pro-apoptotic ligand of ER $\alpha$  (oestrogen receptor)] and 5 $\alpha$ -androstane-3 $\alpha$ ,17 $\beta$ -diol (an inactive androgen) respectively in androgen target tissues, such as the prostate.

A major metabolite of the potent progestin progesterone is pregnanediol (or 5 $\alpha$ -pregnane-3 $\beta$ ,20 $\alpha$ -diol), which is a 3 $\beta$ ,5 $\alpha$ -THS, indicating the importance of the 5 $\alpha$ -pathway in the metabolism of progesterone [1]. Progesterone metabolism via the 5 $\alpha$ -pathway can occur similarly to testosterone metabolism, i.e. progesterone is reduced to 5 $\alpha$ -pregnane-3,20-dione by AKR1D1, which in turn is reduced at the 3-oxo position by AKR1C1–4 (Scheme 1). However, since human AKR1C enzymes also have 20-ketoreductase activity, formation of 20-hydroxy steroids is also possible. Thus, alternatively, progesterone can be first reduced at the 20-oxo position to form 20 $\alpha$ -hydroxyprogesterone, a reaction that is known to be catalysed by AKR1C1 [13]. 20 $\alpha$ -Hydroxyprogesterone can then be reduced by AKR1D1 to form 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one, which in turn can be reduced by AKR1C1–4 enzymes to isomeric 5 $\alpha$ -pregnane-3,20-diols. Thus, for progesterone, there are two possible intermediate 5 $\alpha$ -DHS on the 5 $\alpha$ -pathway of progesterone metabolism, i.e. 5 $\alpha$ -pregnane-3,20-dione and 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one.

In the present study, we have characterized the stereochemical outcomes and kinetic properties of the reduction of three intermediate 5 $\alpha$ -DHS, i.e. 5 $\alpha$ -DHT, 5 $\alpha$ -pregnane-3,20-dione and 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one, catalysed by AKR1C1–4 enzymes. We demonstrate that the 3-oxo reduction of these three 5 $\alpha$ -reduced steroids by all of the human AKR1C enzymes stereospecifically favoured the formation of 3 $\beta$ ,5 $\alpha$ -THS. Our results support differential roles of human AKR1C enzymes in the hepatic metabolism of active testosterone and progesterone. In addition, the activities of AKR1C1–4 enzymes were compared with that of AKR1D1 in the preceding step of the pathway (i.e. the 5 $\alpha$ -reduction). Results suggest that the intermediate 5 $\alpha$ -DHS are unlikely to accumulate in the liver and enter the circulation. Local formation of bioactive 5 $\alpha$ -reduced steroids would thus be dependent upon the presence of AKR1D1 when it co-exists with extrahepatic AKR1C1–3 isoforms.

## EXPERIMENTAL

### Materials

All steroids were obtained from Steraloids. Pyridine nucleotides were purchased from Roche Applied Science. All other reagents were purchased from Sigma–Aldrich and were of ACS (American Chemical Society) grade or better. Recombinant AKR1C1–4 enzymes were overexpressed and purified to homogeneity as described previously [21,22]. Under standard assay conditions, the specific activities of AKR1C1–3 were determined to be 1.8  $\mu\text{mol}/\text{min}$  per mg for AKR1C1, 2.3  $\mu\text{mol}/\text{min}$  per mg for AKR1C2 and 1.3  $\mu\text{mol}/\text{min}$  per mg for AKR1C3 for the NADP<sup>+</sup>-dependent oxidation of 0.2 mM 1-acenaphthenol, the specific activity of AKR1C4 was 0.3  $\mu\text{mol}/\text{min}$  per mg for the NAD<sup>+</sup>-dependent oxidation of 75  $\mu\text{M}$  androsterone and the specific activity of AKR1D1 was 80 nmol/min per mg for the NADPH-dependent reduction of 10  $\mu\text{M}$  testosterone [14,21,23].

### LC (liquid chromatography)–MS analysis

Products for the reduction of ketosteroids catalysed by AKR1C1–4 enzymes were prepared as follows. Reaction mixtures contained 100 mM potassium phosphate buffer (pH 7.0), 20  $\mu\text{M}$  steroid, 0.5 mM NADPH and 4 % methanol in a total volume of 500  $\mu\text{l}$ . The reaction was initiated by the addition of purified enzyme (7.3  $\mu\text{g}$  of AKR1C1, 9.0  $\mu\text{g}$  of AKR1C2, 12.3  $\mu\text{g}$  of AKR1C3 or 5.6  $\mu\text{g}$  of AKR1C4), and for the no-enzyme control buffer was substituted. Systems were incubated at 37 °C and incubation times were 20 min and 90 min for the enzymatic reactions and 90 min for non-enzymatic controls. Reaction mixtures were extracted twice with 1 ml of water-saturated ethyl acetate. The pooled organic extracts were vacuum-dried and the residues were redissolved in 200  $\mu\text{l}$  of methanol.

Normal-phase chiral chromatography for LC–MS experiments was performed using a Waters Alliance 2690 HPLC system. Gradient elution was performed in the linear mode. A Chiralpak IA column (250 mm long  $\times$  4.6 mm diameter, internal diameter 5  $\mu\text{m}$ ; Daicel Chemical Industries) was employed with a flow rate of 1 ml/min. Solvent A was hexanes (Fisher, Optima grade) and solvent B was ethanol/hexanes (1:1, v/v). A linear gradient was used starting with 98.5 % solvent A to 50 % solvent A in 17 min and maintained for 5 min to elute all of the polar compounds and prevent overpressure. At 25 min the gradient was changed to 98.5 % solvent A and kept at 98.5 % to re-equilibrate the column to the initial conditions. The separation was performed at 30  $^{\circ}\text{C}$ .

MS was conducted using a Finnigan TSQ Quantum Ultra AM spectrometer (Thermo Fisher) equipped with an APCI (atmospheric pressure chemical ionization) source operated in the positive-ion mode. Full-scan analysis was conducted in Q3 only in the mass interval 150–400. For MRM (multiple reaction monitoring) analyses, unit resolution was maintained for both parent and product ions. Operating conditions were as follows: vaporizer temperature 450  $^{\circ}\text{C}$ , heated capillary temperature 300  $^{\circ}\text{C}$  with a discharge current of 6  $\mu\text{A}$  applied to the corona needle, and nitrogen was used for the sheath gas, auxiliary gas and ion sweep gas, set at 25, 5 and 3 (in arbitrary units) respectively. CID (collision-induced dissociation) was performed using argon as the collision gas at 1.5 mTorr in the second [r.f. (radio frequency)-only] quadrupole. An additional D.C. offset voltage was applied to the region of the second multipole ion guide (Q0) at 10 V to impart enough translational kinetic energy to the ions so that solvent adduct ions dissociate to form sample ions. Full scanning analyses were performed in the range of  $m/z$  100 to  $m/z$  600. Products of the reactions were identified on the basis of their LC retention times and mass spectra relative to those observed with the authentic standards. LC–APCI/MRM/MS analyses were conducted using  $m/z$  291 ( $[M + H]^+$ ) 273 ( $[M + H - H_2O]^+$ ) (collision energy, 26 eV) for 5 $\alpha$ -DHT;  $m/z$  275 ( $[M + H - H_2O]^+$ ) 259 ( $[M + H - 2H_2O]^+$ ) (collision energy, 26 eV) for 5 $\alpha$ -androstane-3 $\beta$ ,17 $\beta$ -diol;  $m/z$  317 ( $[M + H]^+$ ) 299 ( $[M + H - H_2O]^+$ ) (collision energy, 23 eV) for 5 $\alpha$ -pregnane-3,20-dione;  $m/z$  301 ( $[M + H - H_2O]^+$ ) 283 ( $[M + H - H_2O]^+$ ) (collision energy, 23 eV) for 3 $\beta$ -hydroxy-5 $\alpha$ -pregnan-20-one and 20 $\beta$ -hydroxy-5 $\alpha$ -pregnan-3-one; and  $m/z$  303 ( $[M + H - H_2O]^+$ ) 285 ( $[M + H - H_2O]^+$ ) (collision energy, 23 eV) for 5 $\alpha$ -pregnane-3 $\beta$ ,20 $\beta$ -diols.

### TLC analysis

Samples were prepared in a similar fashion as for LC–MS analysis and applied to Partisil LK6D Silica TLC plates (Whatman). Chromatograms were developed in cyclohexane/ethyl acetate (5:13, v/v). Products were identified by co-migration with authentic standards applied to the same plate following visualization by spraying with acetic acid/sulfuric acid/anisaldehyde (100:2:1, by vol.) and heat.

### Determination of steady-state kinetic parameters

Initial rates of the NADPH-dependent reduction of ketosteroids catalysed by AKR1C1–4 enzymes were measured with a Hitachi F-2500 fluorescence spectrophotometer by monitoring the change in fluorescence emission of NADPH.  $\lambda_{\text{ex}}$  and  $\lambda_{\text{em}}$  wavelengths were set at 340 nm and 450 nm respectively. Changes in fluorescence units were converted into nanomoles of cofactor by using standard curves of fluorescence emission against known NADPH concentrations. Typical reaction samples contained enzyme (1.4  $\mu\text{g}$  of AKR1C1, 1.2  $\mu\text{g}$  of AKR1C2, 1.6  $\mu\text{g}$  of AKR1C3, 0.8  $\mu\text{g}$  of AKR1C4 or 2.1  $\mu\text{g}$  of AKR1D1), NADPH (saturating concentration 8  $\mu\text{M}$  or 25  $\mu\text{M}$ ), various steroid concentrations (0.1  $\mu\text{M}$ –50  $\mu\text{M}$ ), 100 mM potassium phosphate buffer (pH 7.0) and 4 % methanol in a total volume of 1 ml. Reaction mixtures were run at 25  $^{\circ}\text{C}$ . Analysis of kinetic data was carried out as described previously [14]. Data were fitted by non-linear least-squares regression to eqn (1):

$$v = \frac{k_{\text{cat}}[E][S]}{K_m + [S]} \quad (1)$$

or eqn (2):

$$v = \frac{k_{\text{cat}}[E]}{1 + (K_m/[S]) + [S]/K_i} \quad (2)$$

where  $v$  is the initial velocity,  $[E]$  and  $[S]$  are the total molar concentrations of the enzyme and steroid substrate respectively,  $k_{\text{cat}}$  ( $\text{s}^{-1}$ ) is the turnover number,  $K_m$  ( $\mu\text{M}$ ) is the apparent Michaelis–Menten constant for the steroid substrate and  $K_i$  ( $\mu\text{M}$ ) is the apparent dissociation constant for the presumed inhibitory enzyme–substrate complex [24].

## Molecular modelling

Conformations of 5 $\beta$ -DHT bound to AKR1C1 (PDB code 1MRQ) and AKR1C2 (PDB code 1IHI) found previously using the automated docking program AUTODOCK were used as the templates to model the binding of 5 $\beta$ -DHT [25]. The structure of 5 $\beta$ -DHT was retrieved from the co-ordinates of the ternary complex AKR1D1–NADP<sup>+</sup>–5 $\beta$ -DHT (PDB code 3DOP). Two templates were used for the manual docking of 5 $\beta$ -DHT. Template 1 is the productive docking position of 5 $\beta$ -DHT in AKR1C2 for the formation of the 3 $\beta$ -reduced product, i.e. the  $\beta$ -face of the steroid is presented to NADPH. Template 2 is the productive docking position of 5 $\beta$ -DHT in AKR1C1 for the formation of the 3 $\alpha$ -reduced product, i.e. the  $\alpha$ -face of the steroid is presented to NADPH. Docking of 5 $\beta$ -DHT was performed as follows. With each template, 5 $\beta$ -DHT was manually docked in position by overlaying the 3-oxo group of 5 $\beta$ -DHT to that of the template. The docking of 5 $\beta$ -DHT on to the template was examined with the steroids in a similar facial orientation and also in a reversed facial orientation. Positions of 5 $\beta$ -DHT were then adjusted to avoid steric clashing with the surrounding residues if possible without significantly changing the position and orientation of the 3-oxo group. The four docked models were evaluated on the basis of distances to surrounding residues as either ‘allowed’ or ‘disallowed’ ( $<2 \text{ \AA}$ ;  $1 \text{ \AA} = 0.1 \text{ nm}$ ).

## RESULTS

### Reduction of 5 $\beta$ -DHT catalysed by AKR1C1–4

The 3-oxo reduction of 5 $\beta$ -DHT can yield two possible products, 5 $\beta$ -androstane-3 $\beta$ ,17 $\beta$ -diol and 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol. Both synthetic standards are available and could be well separated by TLC (results not shown) and LC–MS methods (Figure 1). The NADPH-dependent reductions of 5 $\beta$ -DHT catalysed by AKR1C1–4 were analysed. All reactions were run to completion, where the relative intensities of the 5 $\beta$ -DHT peak in samples containing AKR1C1–4 were less than 2 % of the 5 $\beta$ -DHT peak in the non-enzymatic control sample. In all samples containing AKR1C enzymes, 5 $\beta$ -androstane-3 $\beta$ ,17 $\beta$ -diol was found to be the predominant product. Only with AKR1C2 did the reaction yield a low but significant amount of 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol (11.4 % of the total products) (Table 1). In contrast, reaction samples with AKR1C1, AKR1C3 and AKR1C4 contained less than 1.5 % of the total products as 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol. No significant epimerase activity was observed with AKR1C3 and AKR1C4, where epimerase activity was seen during the reduction of 5 $\beta$ -DHT and 5 $\beta$ -DHT-17 $\beta$ -sulfate by these enzymes [4,14].

Individual human AKR1C enzymes are known to have different kinetic properties with the same steroid substrate [4,13–15]. This was also true with 5 $\beta$ -DHT.  $k_{\text{cat}}$  and  $K_m$  values for the reduction of 5 $\beta$ -DHT catalysed by AKR1C1–4 isoforms were determined by continuous

spectrofluorimetric assays where the depletion of NADPH was monitored (see the Supplementary Figure S1 at <http://www.BiochemJ.org/bj/437/bj4370053add.htm> for representative results). Thus, for the reduction of 5 $\beta$ -DHT catalysed by AKR1C2, the activity measured represented the total activity, since a mixture of stereoisomeric products were formed. Results are shown in Table 2 (see Supplementary Figure S1 for representative results). AKR1C4 was found to be the most efficient enzyme for the reduction of 5 $\beta$ -DHT with the highest  $k_{\text{cat}}$  and the lowest  $K_{\text{m}}$  values. The catalytic activity of AKR1C1 displayed a  $k_{\text{cat}}$  value that was approximately three times lower and a  $K_{\text{m}}$  that was 26 times higher compared with AKR1C4. The kinetic behaviours of AKR1C2 and AKR1C3 were similar for the reduction of 5 $\beta$ -DHT, both showing a low catalytic efficiency and moderate substrate inhibition.

### Reduction of 5 $\beta$ -pregnane-3,20-dione and 20 $\alpha$ -hydroxy-5 $\beta$ -pregnan-3-one catalysed by AKR1C1–4

5 $\beta$ -Pregnane-3,20-dione and 20 $\alpha$ -hydroxy-5 $\beta$ -pregnan-3-one are the intermediate 5 $\beta$ -DHS on the 5 $\beta$ -pathway of progesterone metabolism, which are subject to metabolic transformation by AKR1C enzymes for the formation of 5 $\beta$ -THS.

For 5 $\beta$ -pregnane-3,20-dione, both the 3- and 20-oxo groups can potentially be reduced by AKR1C enzymes. There are eight possible products for the reaction, which include four monohydroxy products (3 $\alpha$ -hydroxy-5 $\beta$ -pregnan-20-one, 3 $\beta$ -hydroxy-5 $\beta$ -pregnan-20-one, 20 $\alpha$ -hydroxy-5 $\beta$ -pregnan-3-one and 20 $\beta$ -hydroxy-5 $\beta$ -pregnan-3-one) and four dihydroxy products (5 $\beta$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol, 5 $\beta$ -pregnane-3 $\beta$ ,20 $\alpha$ -diol, 5 $\beta$ -pregnane-3 $\alpha$ ,20 $\beta$ -diol and 5 $\beta$ -pregnane-3 $\beta$ ,20 $\beta$ -diol). Synthetic standards for all possible products were available for product authentication by TLC and LC–MS. In LC–MS analysis, 5 $\beta$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol and 5 $\beta$ -pregnane-3 $\beta$ ,20 $\alpha$ -diol could not be separated. However, lack of separation of these two standards by LC–MS had no effect on the results of the experiment, since no product peaks around their retention times were detected in the reaction samples. The retention time of 5 $\beta$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol was close to 20 $\alpha$ -hydroxy-5 $\beta$ -pregnan-3-one in LC–MS analysis; however, they could be well separated with TLC.

It was found by LC–MS analysis and TLC that, for the reduction of 5 $\beta$ -pregnane-3,20-dione catalysed by AKR1C enzymes, 3 $\alpha$ -hydroxy-5 $\beta$ -pregnan-20-one and 5 $\beta$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol were detected as the main products at the end point of the reaction (Figure 2). The distribution between the two products for each AKR1C1–4 enzyme varies, with 5 $\beta$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol as the major product for the AKR1C1 and AKR1C4 reactions and 3 $\alpha$ -hydroxy-5 $\beta$ -pregnan-20-one as the major product for AKR1C2 and AKR1C3 (Table 1). Interestingly, significant transient formation of 20 $\alpha$ -hydroxy-5 $\beta$ -pregnan-3-one was observed at earlier time points of the 5 $\beta$ -pregnane-3,20-dione reaction catalysed by AKR1C1 (Supplementary Figure S2 at <http://www.BiochemJ.org/bj/437/bj4370053add.htm>). Thus, in the reaction catalysed by AKR1C1, two monohydroxy products, 3 $\alpha$ -hydroxy-5 $\beta$ -pregnan-20-one and 20 $\alpha$ -hydroxy-5 $\beta$ -pregnan-3-one, were formed in comparable amounts, each of which was subsequently further converted into 5 $\beta$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol. In contrast, only one monohydroxy product, 3 $\alpha$ -hydroxy-5 $\beta$ -pregnan-20-one, was observed in the reaction catalysed by AKR1C2–4. The distribution between the the monohydroxy and dihydroxy products suggests that formation of the dihydroxy product was much slower for AKR1C2 and AKR1C3 than for AKR1C4.

For the reduction of 20 $\alpha$ -hydroxy-5 $\beta$ -pregnan-3-one catalysed by AKR1C1–4 enzymes, there are two possible products: 5 $\beta$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol and 5 $\beta$ -pregnane-3 $\beta$ ,20 $\alpha$ -diol. Product identification by LC–MS and TLC showed only the formation of 5 $\beta$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol for the reaction catalysed by all four AKR1C enzymes.

Kinetic properties for the reductions of 5 $\alpha$ -pregnane-3,20-dione and 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one catalysed by each AKR1C1–4 enzyme are shown in Table 2 (also see Supplementary Figure S1). With 5 $\alpha$ -pregnane-3,20-dione as the substrate, AKR1C4 was moderately more efficient: its catalytic efficiency was 1.5-, 2.4- and 5.4-fold higher than those of AKR1C1, AKR1C2 and AKR1C3 respectively. This difference in catalytic efficiency stemmed mostly from different  $k_{\text{cat}}$  values, since similar  $K_{\text{m}}$  values were obtained for AKR1C1–4. With the exception of AKR1C4, low degrees of substrate inhibition ( $K_{\text{i}}/K_{\text{m}} > 16$ ) were observed for the reduction of 5 $\alpha$ -pregnane-3,20-dione catalysed by AKR1C1–3. With 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one as the substrate, the differences in catalytic efficiency between AKR1C4 and AKR1C1–3 were more pronounced such that the catalytic efficiency of AKR1C4 was 8.9-, 12- and 15-fold higher than those of AKR1C1, AKR1C2 and AKR1C3 respectively. Low degrees of substrate inhibition ( $K_{\text{i}}/K_{\text{m}} > 15$ ) were also observed for the reduction of 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one catalysed by AKR1C1, AKR1C3 and AKR1C4, but not for that by AKR1C2.

Kinetic properties for the reduction of 3 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-20-one were also examined to compare the 20-oxo reduction activity of AKR1C enzymes with the 3-oxo reduction activity of 5 $\alpha$ -steroids (Table 2). As expected, AKR1C1 displayed the highest  $k_{\text{cat}}$  value. Activities of AKR1C2 and AKR1C3 for this reaction were low. Although the value of  $k_{\text{cat}}$  for AKR1C4 was 4-fold lower than that for AKR1C1, a relatively smaller  $K_{\text{m}}$  of AKR1C4 resulted in a slightly better catalytic efficiency for the enzyme than AKR1C1.

### Reduction of testosterone, progesterone and 20 $\alpha$ -hydroxyprogesterone catalysed by AKR1D1

Kinetic properties for the reduction of testosterone, progesterone and 20 $\alpha$ -hydroxyprogesterone catalysed by AKR1D1 were examined (Table 2). The common feature of these reactions was the observation of potent substrate inhibition. For both testosterone and 20 $\alpha$ -hydroxyprogesterone,  $K_{\text{i}}$  values were determined to be significantly lower than their respective  $K_{\text{m}}$  values. Thus the observed reaction rates were significantly lower than their estimated  $V_{\text{max}}$  values. In the reaction of progesterone, strong substrate inhibition was also observed. The data point of the lowest progesterone concentration displayed the highest reaction rate, so the kinetic parameters for the reaction could not be accurately determined. The rate constant reported was calculated on the basis of highest observed rate.

### Molecular modelling of 5 $\beta$ -DHT binding in AKR1C1–4

Using an automated docking method we have previously found ‘productive’ docked positions of 5 $\beta$ -DHT in AKR1C1 and AKR1C2 to account for the stereospecific formation of 3 $\alpha$ - and 3 $\beta$ -reduced products by the two enzymes respectively [25]. These productive positions of 5 $\beta$ -DHT were used as templates to model 5 $\beta$ -DHT binding. 5 $\beta$ -DHT was manually docked in the productive position of 5 $\beta$ -DHT in AKR1C2 using a similar facial orientation. The resulting model placed the 3-oxo group in position for a reaction in which the  $\alpha$ -face of the steroid faces the 4-pro-*R*-hydride of the cofactor (Figure 3, upper left-hand panel). This model was deemed as ‘allowed’ since no steric conflict with surrounding residues were observed. Using the same template, the facial orientation of the 5 $\beta$ -DHT was inverted to make the  $\beta$ -face of the steroid presented to the cofactor for 3 $\alpha$ -HSD reaction (Figure 3, upper right-hand panel). However, the resulting model is clearly disallowed since the bent structure in 5 $\beta$ -DHT caused the steroid nucleus to clash with the side chain of Trp<sup>227</sup>. Similar docking experiments were performed using the productive position of 5 $\beta$ -DHT in AKR1C1 as the template (the steroid was positioned for the formation of 3 $\beta$ -reduced product) (Figure 3, lower panels). 5 $\beta$ -DHT could not be accommodated in the position of this template in either facial orientation. Our docking experiments revealed that the steroid-binding channel of all human AKR1C enzymes is narrow between residues 54

and 227, and cannot accommodate a 5 $\beta$ -steroid in positions that lead to a 3 $\beta$ -HSD reaction. Of the four isoforms, only AKR1C2 has a valine residue at position 54, whereas the others have the slightly bulky Leu<sup>54</sup>. This would explain why 5 $\beta$ -androstane-3 $\beta$ ,17 $\beta$ -diol was observed as a minor product only with AKR1C2.

## DISCUSSION

Active sex hormones such as testosterone (a potent androgen) and progesterone (a potent progestin) are extensively metabolized to THS in liver for the termination of hormone action. This is achieved by the sequential reduction of the 4-ene moiety and the 3-oxo group (Scheme 1). The four human AKR1C enzymes are implicated to perform reactions following either 5 $\alpha$ -reductase or AKR1D1 to form 5 $\alpha$ - and 5 $\beta$ -THS products respectively. Historically, 5 $\alpha$ -reduced steroids have been mostly regarded as inactive steroids and thus received less attention than their 5 $\beta$ -reduced counterparts. The formation of 5 $\beta$ -reduced steroids is inarguably catabolically important since it is believed to account for two-thirds of the mass of steroids that are inactivated [26]. In the present study, the role of individual AKR1C1–4 enzymes on the 5 $\beta$ -pathways of testosterone and progesterone metabolism was elucidated.

### Stereospecificity of 3-oxoreduction of 5 $\beta$ -DHS catalysed by human AKR1C isoforms

The 3-oxo reduction of 5 $\beta$ -DHT, 5 $\beta$ -pregnane-3,20-dione and 5 $\beta$ -pregnan-20 $\beta$ -3-one catalysed by all four human AKR1C enzymes yielded respective steroid products in the 3 $\beta$ -configuration as the sole or predominant product. This stereospecificity is in stark contrast with the previous observation that for the 3-oxo reduction of 5 $\alpha$ -DHT and the hormone-replacement therapeutic tibolone (a 3 $\alpha$ -3-one steroid) the distribution between 3 $\alpha$ - and 3 $\beta$ -reduced products can vary significantly with each enzyme–substrate combination [4,15]. A comparison between 5 $\alpha$ -DHT and 5 $\beta$ -DHT as substrate for AKR1C1–4 enzymes highlights the effect of the configuration of A/B-ring junction on stereochemical outcome of 3-oxo reduction. When 5 $\alpha$ -DHT was used as the substrate, the reactions catalysed by AKR1C1, 3 and 4 enzymes yielded a mixture of 3 $\alpha$ - and 3 $\beta$ -hydroxy androstanediols in comparable amounts (the ratios between the two products were 1:2.9, 1.6:1 and 3.6:1 respectively), whereas the reaction catalysed by AKR1C2 generated the 3 $\beta$ -reduced steroid as the predominant product (the 3 $\alpha$ /3 $\beta$  ratio was 20:1). In contrast, when 5 $\beta$ -DHT was used as the substrate, the reactions catalysed by all four isoforms predominantly formed the 3 $\beta$ -reduced steroid (the 3 $\alpha$ /3 $\beta$  ratios were 66:1, 7.8:1, 271:1 and 137:1 respectively). Again the AKR1C2 reaction was an exception in that a small but significant amount of 3 $\alpha$ -product was now observed. These results confirmed that the structure of the A-ring significantly affects the stereochemical outcome of the reaction.

Molecular modelling of the binding of 5 $\beta$ -DHT provided the structural basis for the effect of A-ring structure on stereochemistry. 5 $\beta$ -Reduced steroids are structurally distinct in that the 5 $\beta$ -configuration causes a 90° bend in the A/B-ring junction. It was found that a steroid with a bent structure can only be accommodated without steric clashing when its 3 $\beta$ -face is presented to the cofactor so that only the 3 $\beta$ -axial alcohol will form. This restriction is largely caused by the narrow channel formed between the side chains of residues 54 and 227 on the opposite sides of the steroid-binding pocket. The steroid is less restricted in AKR1C2 since the enzyme has a less bulky side chain at position 54 compared with other isoforms.

### Substrate preferences of AKR1C1–4

All four human AKR1C enzymes are able to catalyse ketosteroid reduction at 3-, 17-, and 20-positions of steroids [13]. AKR1C1 is considered mainly as a 20-ketoreductase on the basis of its preference to reduce progesterone, whereas AKR1C2 and AKR1C4 are efficient



3-oxosteroid reductases and AKR1C3 acts as a 17-ketosteroid reductase. Our results in the present study indicate that these assignments can change on the basis of the substrate examined. When 5 $\alpha$ - and 5 $\beta$ -DHT are compared as substrates, with the exception of AKR1C2, human AKR1C enzymes in general displayed higher turnover numbers with the 5 $\alpha$ -reduced steroid substrates. Increased reactivity with 5 $\alpha$ -reduced steroids at the 3-position resulted in comparable reactivity for reduction at the 3-position and the 20-position for AKR1C1. AKR1C2, however, is a poor enzyme with 5 $\alpha$ -reduced steroids for reaction at either the 3- or 20-positions, due to its decreased activity for 3-oxo reduction. Interestingly, AKR1C3 displayed better turnover numbers for 3-ketoreduction (5 $\alpha$ -DHT and 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one) than that for 20-ketoreduction (3 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-20-one), and these turnover numbers were also higher than that for its known 17-ketoreduction activity [13]. AKR1C4 retains its strong preference for reaction at the 3-position with 5 $\alpha$ -reduced substrates as seen with 5 $\beta$ -reduced substrates. These substrate preferences suggest different roles of individual AKR1C1–4 enzymes in systemic (liver) and peripheral steroid hormone metabolism.

### Implications for 5 $\beta$ -THS formation in liver

AKR1D1 is known to be predominantly expressed in liver [27] and is now shown to efficiently catalyse the reduction of testosterone, progesterone and 20 $\alpha$ -hydroxyprogesterone. Strikingly, all three reactions displayed potent substrate inhibition. With testosterone and 20 $\alpha$ -hydroxyprogesterone, the values of  $K_i$ , estimated by fitting the data to the kinetic equation with a substrate inhibition term, were significantly less than their respective values of  $K_m$ . As a result of the potent substrate inhibition, the value of  $k_{cat}$  predicted by data analysis could not be effectively reached in these reactions. In fact, the observed maximum rate constants were 5- and 10-fold lower than their predicted  $k_{cat}$  values for testosterone and 20 $\alpha$ -hydroxyprogesterone respectively. With progesterone, values of  $k_{cat}$  and  $K_m$  could not be accurately determined; the available data indicated strong substrate inhibition that resulted in low observed reaction rates. When the kinetics of the step catalysed by AKR1D1 were compared with the subsequent step catalysed by AKR1C1–4, the catalytic efficiencies of AKR1D1 were found to be much lower than those of AKR1C4, which displayed the highest catalytic efficiency among human AKR1C isoforms for 3-oxo reduction with the 5 $\alpha$ -reduced substrates. This would suggest that the formation of 5 $\alpha$ -DHS (the reaction catalysed by AKR1D1) occurs less efficiently than the disappearance of 5 $\alpha$ -DHS (the reaction catalysed by AKR1C1–4 enzymes). Taken together, it appears that the intermediate 5 $\alpha$ -DHS metabolites are prevented from accumulating in the liver by strong substrate inhibition in the AKR1D1 reaction and by the fast reaction catalysed by AKR1C4 leading to their metabolism to 5 $\beta$ -THS. This is consistent with the observation of very low levels of 5 $\alpha$ -pregnane-3,20-dione in circulation [28]. Since the build-up of 5 $\alpha$ -pregnane-3,20-dione is predicted not to occur in the liver, a different ligand may be responsible for the activation of PXR in this organ.

Expression of human AKR1C isoforms in fresh liver biopsies were found to follow the rank order of AKR1C4>AKR1C1 > AKR1C2>AKR1C3 [29]. In addition, AKR1C4 has displayed the highest catalytic efficiency for 3-oxo reduction with almost all steroid substrates studied previously [4,13,14]. This is also the case with 5 $\alpha$ -DHS studied in the present work, although the difference is more pronounced with 5 $\alpha$ -DHT and 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one, but less so with 5 $\alpha$ -pregnane-3,20-dione. Thus, being the most abundant and catalytically efficient enzyme, AKR1C4 is set to be the most important 3-ketoreductase for the formation of 3 $\alpha$ ,5 $\alpha$ -THS in this organ. More specifically for the 5 $\alpha$ -metabolic pathways, AKR1C4 is clearly the principal enzyme responsible for the formation of 3 $\alpha$ ,5 $\alpha$ -THS of testosterone, whereas all AKR1C1–4 isoforms are likely to contribute to the formation of 3 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-20-one and 5 $\alpha$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol from 5 $\alpha$ -

pregnane-3,20-dione and the formation of 5 $\alpha$ -pregnane-3 $\alpha$ ,20 $\alpha$ -diol from 20 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-3-one (Scheme 2).

### Implications for peripheral formation of 5 $\beta$ -reduced steroids

In liver, 5 $\alpha$ -DHS are unlikely to accumulate to high levels and enter the circulation, since they would be rapidly metabolized by AKR1C4. However, 5 $\alpha$ -DHS may accumulate in tissues in which AKR1D1 and AKR1C1–3 are co-expressed since these extrahepatic human AKR1C isoforms displayed lower catalytic efficiencies for 5 $\alpha$ -THS formation. The expression levels of AKR1D1 and AKR1C1–3 in a given peripheral tissue will control the identity and level of the 5 $\alpha$ -reduced steroid metabolites formed. 5 $\alpha$ -Reduced steroids are increasingly being recognized as active compounds with important regulating functions [8,9,11,30,31]. It is most likely that the active 5 $\alpha$ -steroids are formed locally by AKR1D1 and AKR1C1–3 enzymes. Indeed, AKR1D1 has been found to be highly expressed in the placenta and myometrium where 5 $\alpha$ -pregnane-3,20-dione has been implied to act as a tocolytic hormone and prevent parturition [11]. 5 $\alpha$ -Pregnane-3,20-dione can decrease uterine sensitivity to the uterotonic peptide hormone oxytocin by binding directly to the uterine oxytocin receptor [30], and also can act through PXR in regulating uterine contractility [31].

It is well established that progesterone and its metabolites are important neurosteroids. 3 $\alpha$ -hydroxy-5 $\alpha$ -pregnan-20-one and its 5 $\alpha$ -isomer 3 $\beta$ -hydroxy-5 $\alpha$ -pregnan-20-one are highly potent positive modulators of the GABA<sub>A</sub> receptor and exert differential effects on the GABA<sub>C</sub> receptor (where GABA is  $\gamma$ -aminobutyric acid) [8,32]. It is believed that biosynthesis of these steroids occurs in the central nervous system. Although it is not known whether AKR1D1 is expressed in human brain, expression and activities of 5 $\alpha$ -reductase and AKR1C1–3 in human brain have been demonstrated previously [33,34]. However, 5 $\alpha$ -reductase and its products have been found in the quail brain, and progesterone was found to be metabolized to 5 $\alpha$ -pregnane-3,20-dione and 3 $\beta$ -hydroxy-5 $\alpha$ -pregnan-20-one in the brains of 1-day-old chicks [35,36]. Thus it is highly probable that these two 5 $\alpha$ -pregnane steroids are also formed locally in human brain by AKR1D1 and AKR1C1–3.

AKR expression can be regulated by factors such as hormonal status and oxidative stress [37,38], which may explain the changes in circulating levels of progesterone metabolites during female menstrual cycle and pregnancy [28,39]. Dysregulation in AKR expression may also contribute to the abnormal plasma concentrations of neurosteroids observed in diseases such as the premenstrual dysphoric disorder [40], depression disorder [41] and chronic fatigue syndrome [42].

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

### Acknowledgments

#### FUNDING

This work was supported by the National Institutes of Health [grant numbers R01-DK47015, R01-CA90744 and P30 ES015857 (to T.M.P)] and by a FOCUS Junior Faculty Investigator Award (to Y.J.) for Research in Woman's Health funded by the Edna G. Kynett Memorial Foundation.

### Abbreviations used

<b>AKR</b>	aldo-keto reductase
<b>APCI</b>	atmospheric pressure chemical ionization


<b>HSD</b>	hydroxysteroid dehydrogenase
<b>DHS</b>	dihydrosteroid(s)
<b>5 / -DHT</b>	5 / -dihydrotestosterone
<b>LC</b>	liquid chromatography
<b>MRM</b>	multiple reaction monitoring
<b>PXR</b>	pregnane X receptor
<b>THS</b>	tetrahydrosteroid(s)

## References

1. Roberts S, Szego CM. Biochemistry of the steroid hormones. *Annu Rev Biochem.* 1955; 24:543–596. [PubMed: 13249365]
2. Tomkins GM. Enzymatic mechanisms of hormone metabolism. I Oxidation-reduction of the steroid nucleus. *Recent Prog Horm Res.* 1956; 12:125–133. [PubMed: 13401053]
3. Russell DW, Wilson JD. Steroid 5 $\alpha$ -reductase: two genes/two enzymes. *Annu Rev Biochem.* 1994; 63:25–61. [PubMed: 7979239]
4. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B, Penning TM. Human cytosolic 3 $\alpha$ -hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3 $\alpha$ -hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. *J Biol Chem.* 2004; 279:10784–10795. [PubMed: 14672942]
5. Jez JM, Flynn TG, Penning TM. A new nomenclature for the aldo-keto reductase superfamily. *Biochem Pharmacol.* 1997; 54:639–647. [PubMed: 9310340]
6. Kondo KH, Kai MH, Setoguchi Y, Eggertsen G, Sjoblom P, Setoguchi T, Okuda KI, Bjorkhem I. Cloning and expression of cDNA of human 4 $\alpha$ -3-oxosteroid 5 $\alpha$ -reductase and substrate specificity of the expressed enzyme. *Eur J Biochem.* 1994; 219:357–363. [PubMed: 7508385]
7. Moore LB, Parks DJ, Jones SA, Bledsoe RK, Consler TG, Stimmel JB, Goodwin B, Liddle C, Blanchard SG, Willson TM, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. *J Biol Chem.* 2000; 275:15122–15127. [PubMed: 10748001]
8. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABAA receptor. *Nat Rev Neurosci.* 2005; 6:565–575. [PubMed: 15959466]
9. Perusquia M, Navarrete E, Gonzalez L, Villalon CM. The modulatory role of androgens and progestins in the induction of vasorelaxation in human umbilical artery. *Life Sci.* 2007; 81:993–1002. [PubMed: 17804019]
10. Sheehan PM. A possible role for progesterone metabolites in human parturition. *Aust NZ J Obstet Gynaecol.* 2006; 46:159–163.
11. Sheehan PM, Rice GE, Moses EK, Brennecke SP. 5 $\alpha$ -Dihydroprogesterone and steroid 5 $\alpha$ -reductase decrease in association with human parturition at term. *Mol Hum Reprod.* 2005; 11:495–501. [PubMed: 16123077]
12. Penning TM. Hydroxysteroid dehydrogenases and pre-receptor regulation of steroid hormone action. *Hum Reprod Update.* 2003; 9:193–205. [PubMed: 12861966]
13. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K. Human 3 $\alpha$ -hydroxysteroid dehydrogenase isoforms (AKR1C1–AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. *Biochem J.* 2000; 351:67–77. [PubMed: 10998348]
14. Jin Y, Duan L, Lee SH, Kloosterboer HJ, Blair IA, Penning TM. Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase superfamily catalyze reduction of conjugated steroids: implications for phase I and phase II steroid hormone metabolism. *J Biol Chem.* 2009; 284:10013–10022. [PubMed: 19218247]


15. Steckelbroeck S, Jin Y, Oyesanmi B, Kloosterboer HJ, Penning TM. Tibolone is metabolized by the 3- $\beta$ -hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a  $5^{(10)}$ - $3$ -ketosteroid. *Mol Pharmacol*. 2004; 66:1702–1711. [PubMed: 15383625]
16. Deyashiki Y, Taniguchi H, Amano T, Nakayama T, Hara A, Sawada H. Structural and functional comparison of two human liver dihydrodiol dehydrogenases associated with 3- $\beta$ -hydroxysteroid dehydrogenase activity. *Biochem J*. 1992; 282:741–746. [PubMed: 1554355]
17. Higaki Y, Usami N, Shintani S, Ishikura S, El-Kabbani O, Hara A. Selective and potent inhibitors of human 20 $\beta$ -hydroxysteroid dehydrogenase (AKR1C1) that metabolizes neurosteroids derived from progesterone. *Chem–Biol Interact*. 2003;143–144. 503–513.
18. Matsuura K, Shiraishi H, Hara A, Sato K, Deyashiki Y, Ninomiya M, Sakai S. Identification of a principal mRNA species for human 3- $\beta$ -hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. *J Biochem*. 1998; 124:940–946. [PubMed: 9792917]
19. Trauger JW, Jiang A, Stearns BA, LoGrasso PV. Kinetics of allopregnanolone formation catalyzed by human 3- $\beta$ -hydroxysteroid dehydrogenase type III (AKR1C2). *Biochemistry*. 2002; 41:13451–13459. [PubMed: 12416991]
20. Usami N, Yamamoto T, Shintani S, Ishikura S, Higaki Y, Katagiri Y, Hara A. Substrate specificity of human 3(20)- $\beta$ -hydroxysteroid dehydrogenase for neurosteroids and its inhibition by benzodiazepines. *Biol Pharm Bull*. 2002; 25:441–445. [PubMed: 11995921]
21. Burczynski ME, Harvey RG, Penning TM. Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo. *Biochemistry*. 1999; 38:10626. [PubMed: 10441160]
22. Ratnam K, Ma H, Penning TM. The arginine 276 anchor for NADP(H) dictates fluorescence kinetic transients in 3- $\beta$ -hydroxysteroid dehydrogenase, a representative aldo-keto reductase. *Biochemistry*. 1999; 38:7856–7864. [PubMed: 10387026]
23. Di Costanzo L, Drury JE, Penning TM, Christianson DW. Crystal structure of human liver 4- $\beta$ -oxosteroid 5 $\alpha$ -reductase (AKR1D1) and implications for substrate binding and catalysis. *J Biol Chem*. 2008; 283:16830–16839. [PubMed: 18407998]
24. Shen P, Larter R. Role of substrate inhibition kinetics in enzymatic chemical oscillations. *Biophys J*. 1994; 67:1414–1428. [PubMed: 7819481]
25. Jin Y, Penning TM. Molecular docking simulations of steroid substrates into human cytosolic hydroxysteroid dehydrogenases (AKR1C1 and AKR1C2): insights into positional and stereochemical preferences. *Steroids*. 2006; 71:380–391. [PubMed: 16455123]
26. Palermo M, Marazzi MG, Hughes BA, Stewart PM, Clayton PT, Shackleton CH. Human 4- $\beta$ -oxosteroid 5 $\alpha$ -reductase (AKR1D1) deficiency and steroid metabolism. *Steroids*. 2008; 73:417–423. [PubMed: 18243262]
27. Charbonneau A, The VL. Genomic organization of a human 5 $\alpha$ -reductase and its pseudogene and substrate selectivity of the expressed enzyme. *Biochim Biophys Acta*. 2001; 1517:228–235. [PubMed: 11342103]
28. Pearson Murphy BE, Allison CM. Determination of progesterone and some of its neuroactive ring A-reduced metabolites in human serum. *J Steroid Biochem Mol Biol*. 2000; 74:137–142. [PubMed: 11086232]
29. Steckelbroeck S, Oyesanmi B, Jin Y, Lee SH, Kloosterboer HJ, Penning TM. Tibolone metabolism in human liver is catalyzed by 3- $\beta$ -hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily. *J Pharmacol Exp Ther*. 2006; 316:1300–1309. [PubMed: 16339391]
30. Grazzini E, Guillon G, Mouillac B, Zingg HH. Inhibition of oxytocin receptor function by direct binding of progesterone. *Nature*. 1998; 392:509–512. [PubMed: 9548257]
31. Mitchell BF, Mitchell JM, Chowdhury J, Tougas M, Engelen SM, Senff N, Heijnen I, Moore JT, Goodwin B, Wong S, Davidge ST. Metabolites of progesterone and the pregnane X receptor: a novel pathway regulating uterine contractility in pregnancy? *Am J Obstet Gynecol*. 2005; 192:1304–1313. [PubMed: 15846226]

32. Morris KD, Moorefield CN, Amin J. Differential modulation of the  $\gamma$ -aminobutyric acid type C receptor by neuroactive steroids. *Mol Pharmacol*. 1999; 56:752–759. [PubMed: 10496958]
33. Steckelbroeck S, Watzka M, Reichelt R, Hans VH, Stoffel-Wagner B, Heidrich DD, Schramm J, Bidlingmaier F, Klingmuller D. Characterization of the 5 $\alpha$ -reductase-3 $\beta$ -hydroxysteroid dehydrogenase complex in the human brain. *J Clin Endocrinol Metab*. 2001; 86:1324–1331. [PubMed: 11238528]
34. Stoffel-Wagner B, Watzka M, Steckelbroeck S, Wickert L, Schramm J, Romalo G, Klingmuller D, Schweikert HU. Expression of 5 $\alpha$ -reductase in the human temporal lobe of children and adults. *J Clin Endocrinol Metab*. 1998; 83:3636–3642. [PubMed: 9768677]
35. Tsutsui K, Matsunaga M, Miyabara H, Ukena K. Neurosteroid biosynthesis in the quail brain: a review. *J Exp Zool A Comp Exp Biol*. 2006; 305:733–742. [PubMed: 16902960]
36. Sujkovic E, Mileusnic R, Fry JP. Metabolism of neuroactive steroids in day-old chick brain. *J Neurochem*. 2009; 109:348–359. [PubMed: 19200338]
37. Jin Y, Penning TM. Aldo-keto reductases and bioactivation/detoxication. *Annu Rev Pharmacol Toxicol*. 2007; 47:263–292. [PubMed: 16970545]
38. Lou H, Du S, Ji Q, Stolz A. Induction of AKR1C2 by phase II inducers: identification of a distal consensus antioxidant response element regulated by NRF2. *Mol Pharmacol*. 2006; 69:1662–1672. [PubMed: 16478829]
39. Hill M, Cibula D, Havlikova H, Kancheva L, Fait T, Kancheva R, Parizek A, Starka L. Circulating levels of pregnanolone isomers during the third trimester of human pregnancy. *J Steroid Biochem Mol Biol*. 2007; 105:166–175. [PubMed: 17583491]
40. Monteleone P, Luisi S, Tonetti A, Bernardi F, Genazzani AD, Luisi M, Petraglia F, Genazzani AR. Allopregnanolone concentrations and premenstrual syndrome. *Eur J Endocrinol*. 2000; 142:269–273. [PubMed: 10700721]
41. van Broekhoven F, Verkes RJ. Neurosteroids in depression: a review. *Psychopharmacology*. 2003; 165:97–110. [PubMed: 12420152]
42. Murphy BE, Abbott FV, Allison CM, Watts C, Ghadirian AM. Elevated levels of some neuroactive progesterone metabolites, particularly isopregnanolone, in women with chronic fatigue syndrome. *Psychoneuroendocrinology*. 2004; 29:245–268. [PubMed: 14604604]




**Figure 1. Product characterization by LC-MS for the reduction of 5 $\beta$ -DHT catalysed by human AKR1C isoforms**

(A) Ion chromatograms (*m/z* 250–320) of authentic standards. 3 $\beta$ -ol, 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol; 3 $\alpha$ -ol, 5 $\beta$ -androstane-3 $\alpha$ ,17 $\beta$ -diol. (B–F) Corresponding ion chromatograms of reaction samples containing no enzyme (B) and AKR1C1–4 (C–F). Samples were prepared as described in the Experimental section. The disappearance of substrate in each reaction sample containing enzyme indicated that the reaction had reached the end point.



**Figure 2. Product characterizations by LC-MS for the reduction of 5-pregnane-3,20-dione catalysed by human AKR1C isoforms**


(A) and (B) Ion chromatograms ( $m/z$  250–320) of authentic standards. 3,20-dione, 5-pregnane-3,20-dione; 3-ol, 3-hydroxy-5-pregnan-20-one; 3-ol, 3-hydroxy-5-pregnan-20-one; 20-ol, 20-hydroxy-5-pregnan-3-one; 20-ol, 20-hydroxy-5-pregnan-3-one; 3,20-diol, 5-pregnane-3,20-diol; 3,20-diol, 5-pregnane-3,20-diol; 3,20-diol, 5-pregnane-3,20-diol. (C–G) Ion chromatograms of reaction samples containing no enzyme (C) and AKR1C1–4 (D–G). Samples were prepared as described in the Experimental section. The disappearance of substrate in each reaction sample containing enzyme indicated that the reaction had reached the end point.




**Figure 3. Docking of 5-DHT into AKR1C active sites**

Details of the model building are given in the Experimental section. Residues in the enzyme active sites are shown in blue. The cofactor is shown in purple, and the 5-DHT template is shown in white. Docked 5-DHT is shown in green (sterically allowed position) or red (sterically disallowed position). In the upper panels, the 5-DHT template was positioned for 3 $\beta$ -reduction in AKR1C2. Upper left-hand panel, 5-DHT docked on the template position so that the facial orientation of the A-ring was the same. Upper right-hand panel, 5-DHT docked on the template position so that the facial orientation of the A-ring was inverted. In the lower panels, the 5-DHT template was positioned for 3 $\alpha$ -reduction in AKR1C1. Lower left-hand panel, 5-DHT docked on the template position so that the facial orientation of the A-ring was the same. Lower right-hand panel, 5-DHT docked on the template position so that the facial orientation of the A-ring was inverted. The Figures were prepared using Swiss-PDBViewer.





**Scheme 1. Pathways of steroid metabolism leading to THS formation (A) and structures of the intermediate 5 -DHS in the pathways of testosterone and progesterone metabolism (B)**  
S, steroid.

**Scheme 2.**

Proposed roles of AKR enzymes on the 5 $\beta$ -pathways of (A) testosterone and (B) progesterone metabolism

**Table 1**  
**Product distribution for the reduction of 5 -DHT and 5 -pregnane-3,20-dione catalysed by human AKR1C enzymes**

For 5 -DHT reduction, 3 - and 3 - products were 5 -androstane-3 ,17 -diol and 5 -androstane-3 ,17 -diol. There was no significant difference in product distribution between samples from 20 min and 90 min incubations. For 5 -pregnane-3,20-dione reduction, 3 -and 3 ,20 - products were 3 -hydroxy-5 -pregnan-20-one and 5 -pregnane-3 ,20 -diol. Values are shown as percentage of total.

Enzyme	Substrate . . . 5 -DHT		5 -pregnane-3,20-dione	
	3 -	3 -	3 -	3 ,20 -
AKR1C1	98.5	1.5	14.2	85.8
AKR1C2	88.6	11.4	66.2	33.8
AKR1C3	99.6	0.4	76.6	23.4
AKR1C4	99.3	0.7	22.4	77.6

**Table 2**  
**Kinetic parameters for the reactions catalysed by AKR in the 5 $\alpha$ -pathway for the metabolism of testosterone and progesterone**  
 Steady-state parameters were determined using a fluorimetric assay. Values are given as means  $\pm$  S.D. ( $n > 2$ ). n.a., not available.

Substrate (reaction)	Enzyme	$k_{\text{cat}}$ ( $\text{min}^{-1}$ )	$K_m$ ( $\mu\text{M}$ )	$k_{\text{cat}}/K_m$ ( $\text{min}^{-1} \cdot \text{M}^{-1}$ ) $\times 10^6$	$K_i$ ( $\mu\text{M}$ )
5 $\alpha$ -DHT (3 $\alpha$ -oxo reduction)	AKR1C1	1.7 $\pm$ 0.1	5.2 $\pm$ 0.6	0.33	—
	AKR1C2	0.9 $\pm$ 0.1	0.8 $\pm$ 0.1	1.1	4.0 $\pm$ 0.2
	AKR1C3	1.2 $\pm$ 0.2	1.4 $\pm$ 0.3	0.8	5.5 $\pm$ 1.0
	AKR1C4	4.7 $\pm$ 0.3	0.2 $\pm$ 0.05	23.5	—
5 $\alpha$ -Pregnane-3,20-dione (3 $\alpha$ - and 20-oxo reduction)	AKR1C1	4.3 $\pm$ 0.2	0.4 $\pm$ 0.1	10.8	24 $\pm$ 3
	AKR1C2	2.0 $\pm$ 0.2	0.3 $\pm$ 0.1	6.7	4.7 $\pm$ 1.2
	AKR1C3	0.9 $\pm$ 0.3	0.3 $\pm$ 0.1	3.0	5.7 $\pm$ 1.3
	AKR1C4	4.9 $\pm$ 0.1	0.3 $\pm$ 0.06	16.3	—
20 $\alpha$ -Hydroxy-5 $\alpha$ -pregnan-3-one (3 $\alpha$ -oxo reduction)	AKR1C1	2.1 $\pm$ 0.1	1.3 $\pm$ 0.1	1.6	28.5 $\pm$ 0.9
	AKR1C2	0.6 $\pm$ 0.1	0.5 $\pm$ 0.1	1.2	—
	AKR1C3	1.6 $\pm$ 0.3	1.7 $\pm$ 0.2	0.94	26 $\pm$ 3
	AKR1C4	4.3 $\pm$ 0.6	0.3 $\pm$ 0.1	14.3	8.2 $\pm$ 2.5
3 $\alpha$ -Hydroxy-5 $\alpha$ -pregnan-20-one (20-oxo reduction)	AKR1C1	4.0 $\pm$ 0.2	1.4 $\pm$ 0.2	2.9	—
	AKR1C2	0.9 $\pm$ 0.1	1.2 $\pm$ 0.4	0.75	22 $\pm$ 10
	AKR1C3	0.4 $\pm$ 0.04	1.3 $\pm$ 0.2	0.31	—
	AKR1C4	1.5 $\pm$ 0.05	0.4 $\pm$ 0.07	3.8	—
Testosterone (5 $\alpha$ -reduction)	AKR1D1	4.7 $\pm$ 2.1	1.2 $\pm$ 0.7	3.9	0.4 $\pm$ 0.2
Progesterone (5 $\alpha$ -reduction)*	AKR1D1	(0.21 $\pm$ 0.03)	(< 0.1)	n.a.	n.a.
20 $\alpha$ -Hydroxyprogesterone (5 $\alpha$ -reduction)	AKR1D1	12.3 $\pm$ 3.1	1.4 $\pm$ 0.4	8.8	0.06 $\pm$ 0.02

\* For the reduction of progesterone catalysed by AKR1D1, the observed maximum rate constant was reported.